Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 3241 to 3244 of 3244 entries
Sorted by: Best Match Show Resources per page
Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review.

British journal of cancer

Laszlo HE, Seward E, Ayling RM, Lake J, Malhi A, Stephens C, Pritchard-Jones K, Chung D, Hackshaw A, Machesney M.
PMID: 34903843
Br J Cancer. 2021 Dec 13; doi: 10.1038/s41416-021-01653-x. Epub 2021 Dec 13.

BACKGROUND: We evaluated whether faecal immunochemical testing (FIT) can rule out colorectal cancer (CRC) among patients presenting with 'high-risk' symptoms requiring definitive investigation.METHODS: Three thousand five hundred and ninety-six symptomatic patients referred to the standard urgent CRC pathway were...

Cite
Laszlo HE, Seward E, Ayling RM, et al. Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review. Br J Cancer. 2021;doi: 10.1038/s41416-021-01653-x.
Laszlo, H. E., Seward, E., Ayling, R. M., Lake, J., Malhi, A., Stephens, C., Pritchard-Jones, K., Chung, D., Hackshaw, A., & Machesney, M. (2021). Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review. British journal of cancer, . https://doi.org/10.1038/s41416-021-01653-x
Laszlo, Helga E, et al. "Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review." British journal of cancer vol. (2021). doi: https://doi.org/10.1038/s41416-021-01653-x
Laszlo HE, Seward E, Ayling RM, Lake J, Malhi A, Stephens C, Pritchard-Jones K, Chung D, Hackshaw A, Machesney M. Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review. Br J Cancer. 2021 Dec 13; doi: 10.1038/s41416-021-01653-x. Epub 2021 Dec 13. PMID: 34903843.
Copy Download .nbib Format: NLM
IgA Plasma Cells Are Long-Lived Residents of Gut and Bone Marrow That Express Isotype- and Tissue-Specific Gene Expression Patterns.

Frontiers in immunology

Wilmore JR, Gaudette BT, Gómez Atria D, Rosenthal RL, Reiser SK, Meng W, Rosenfeld AM, Luning Prak ET, Allman D.
PMID: 35003110
Front Immunol. 2021 Dec 24;12:791095. doi: 10.3389/fimmu.2021.791095. eCollection 2021.

Antibody secreting plasma cells are made in response to a variety of pathogenic and commensal microbes. While all plasma cells express a core gene transcription program that allows them to secrete large quantities of immunoglobulin, unique transcriptional profiles are...

Cite
Wilmore JR, Gaudette BT, Gómez Atria D, et al. IgA Plasma Cells Are Long-Lived Residents of Gut and Bone Marrow That Express Isotype- and Tissue-Specific Gene Expression Patterns. Front Immunol. 2021;12:791095doi: 10.3389/fimmu.2021.791095.
Wilmore, J. R., Gaudette, B. T., Gómez Atria, D., Rosenthal, R. L., Reiser, S. K., Meng, W., Rosenfeld, A. M., Luning Prak, E. T., & Allman, D. (2021). IgA Plasma Cells Are Long-Lived Residents of Gut and Bone Marrow That Express Isotype- and Tissue-Specific Gene Expression Patterns. Frontiers in immunology, 12791095. https://doi.org/10.3389/fimmu.2021.791095
Wilmore, Joel R, et al. "IgA Plasma Cells Are Long-Lived Residents of Gut and Bone Marrow That Express Isotype- and Tissue-Specific Gene Expression Patterns." Frontiers in immunology vol. 12 (2021): 791095. doi: https://doi.org/10.3389/fimmu.2021.791095
Wilmore JR, Gaudette BT, Gómez Atria D, Rosenthal RL, Reiser SK, Meng W, Rosenfeld AM, Luning Prak ET, Allman D. IgA Plasma Cells Are Long-Lived Residents of Gut and Bone Marrow That Express Isotype- and Tissue-Specific Gene Expression Patterns. Front Immunol. 2021 Dec 24;12:791095. doi: 10.3389/fimmu.2021.791095. eCollection 2021. PMID: 35003110; PMCID: PMC8739487.
Copy Download .nbib Format: NLM
5q11.2 deletion syndrome revisited-Further narrowing of the smallest region of overlap for the main clinical characteristics of the syndrome.

American journal of medical genetics. Part A

Bayat A, Bayat M, Broers C, Polstra AM, Zwijnenburg PJG, Hjortshøj TD.
PMID: 34322994
Am J Med Genet A. 2021 Dec;185(12):3844-3850. doi: 10.1002/ajmg.a.62428. Epub 2021 Jul 28.

Microdeletions at 5q11.2 are rare. Subjects show a phenotypic spectrum that overlaps CHARGE syndrome and 22q11.2 deletion syndrome. A growing number of subjects present with learning difficulty and/or intellectual disability, immune deficiency, congenital heart malformation, and dysmorphism. DHX29 and...

Cite
Bayat A, Bayat M, Broers C, et al. 5q11.2 deletion syndrome revisited-Further narrowing of the smallest region of overlap for the main clinical characteristics of the syndrome. Am J Med Genet A. 2021;185(12):3844-3850doi: 10.1002/ajmg.a.62428.
Bayat, A., Bayat, M., Broers, C., Polstra, A. M., Zwijnenburg, P. J. G., & Hjortshøj, T. D. (2021). 5q11.2 deletion syndrome revisited-Further narrowing of the smallest region of overlap for the main clinical characteristics of the syndrome. American journal of medical genetics. Part A, 185(12), 3844-3850. https://doi.org/10.1002/ajmg.a.62428
Bayat, Allan, et al. "5q11.2 deletion syndrome revisited-Further narrowing of the smallest region of overlap for the main clinical characteristics of the syndrome." American journal of medical genetics. Part A vol. 185,12 (2021): 3844-3850. doi: https://doi.org/10.1002/ajmg.a.62428
Bayat A, Bayat M, Broers C, Polstra AM, Zwijnenburg PJG, Hjortshøj TD. 5q11.2 deletion syndrome revisited-Further narrowing of the smallest region of overlap for the main clinical characteristics of the syndrome. Am J Med Genet A. 2021 Dec;185(12):3844-3850. doi: 10.1002/ajmg.a.62428. Epub 2021 Jul 28. PMID: 34322994.
Copy Download .nbib Format: NLM
Efficacy, safety, and immunogenicity of the .

EClinicalMedicine

Frenck RW, Conti V, Ferruzzi P, Ndiaye AGW, Parker S, McNeal MM, Dickey M, Granada JP, Cilio GL, De Ryck I, Necchi F, Suvarnapunya AE, Rossi O, Acquaviva A, Chandrasekaran L, Clarkson KA, Auerbach J, Marchetti E, Kaminski RW, Micoli F, Rappuoli R, Saul A, Martin LB, Podda A.
PMID: 34430837
EClinicalMedicine. 2021 Aug 13;39:101076. doi: 10.1016/j.eclinm.2021.101076. eCollection 2021 Sep.

BACKGROUND: Shigellosis accounts for substantial morbidity and mortality worldwide and is the second most common cause of moderate and severe diarrhoea in children.METHODS: This phase 2b study (NCT03527173), conducted between August 2018 and November 2019, evaluated vaccine efficacy (VE),...

Cite
Frenck RW, Conti V, Ferruzzi P, et al. Efficacy, safety, and immunogenicity of the . EClinicalMedicine. 2021;39:101076doi: 10.1016/j.eclinm.2021.101076.
Frenck, R. W., Conti, V., Ferruzzi, P., Ndiaye, A. G. W., Parker, S., McNeal, M. M., Dickey, M., Granada, J. P., Cilio, G. L., De Ryck, I., Necchi, F., Suvarnapunya, A. E., Rossi, O., Acquaviva, A., Chandrasekaran, L., Clarkson, K. A., Auerbach, J., Marchetti, E., Kaminski, R. W., Micoli, F., Rappuoli, R., Saul, A., Martin, L. B., & Podda, A. (2021). Efficacy, safety, and immunogenicity of the . EClinicalMedicine, 39101076. https://doi.org/10.1016/j.eclinm.2021.101076
Frenck, Robert W, et al. "Efficacy, safety, and immunogenicity of the ." EClinicalMedicine vol. 39 (2021): 101076. doi: https://doi.org/10.1016/j.eclinm.2021.101076
Frenck RW, Conti V, Ferruzzi P, Ndiaye AGW, Parker S, McNeal MM, Dickey M, Granada JP, Cilio GL, De Ryck I, Necchi F, Suvarnapunya AE, Rossi O, Acquaviva A, Chandrasekaran L, Clarkson KA, Auerbach J, Marchetti E, Kaminski RW, Micoli F, Rappuoli R, Saul A, Martin LB, Podda A. Efficacy, safety, and immunogenicity of the . EClinicalMedicine. 2021 Aug 13;39:101076. doi: 10.1016/j.eclinm.2021.101076. eCollection 2021 Sep. PMID: 34430837; PMCID: PMC8367798.
Copy Download .nbib Format: NLM
Showing 3241 to 3244 of 3244 entries